Stockscreener 앱 받기
28.21
0.21%
-0.06
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Mineralys (NASDAQ: MLYS) insider plans sale after $2,696,321.98 June stock deal - Stock Titan
Mineralys Plunges As Costly Royalty Deal Shocks Wall Street - TipRanks
People on the Move: Jessica Wagner Keliher, SPHR, Joins Mineralys Therapeutics as Vice President, Talent Management - BioBuzz
Timothy G. Youngquist 2020 Irrevocable Trust Takes $2.72 Million Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys (MLYS) Q2 2026 Earnings Call Transcript - AOL.com
Mineralys Builds $661 Million War Chest Ahead of FDA Decision - MyChesCo
Mineralys Grants Equity Awards to New Medical Chief - MyChesCo
TimesSquare Capital Management LLC Invests $6.36 Million in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys (NASDAQ: MLYS) insider adds 417-share sale to six-figure run - Stock Titan
Mineralys Therapeutics, Inc. $MLYS Shares Bought by Bank of America Corp DE - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Downgraded by Zacks Research to "Strong Sell" - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Q3 EPS Estimate for Mineralys Therapeutics Raised by Analyst - MarketBeat
Mineralys Therapeutics (NASDAQ: MLYS) insider files Form 144 to sell 14,056 shares - Stock Titan
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $40 to $56 - Moomoo
What is HC Wainwright's Estimate for MLYS FY2030 Earnings? - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Wells Fargo Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $55 - Moomoo
BofA Securities Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Announces Target Price $49 - Moomoo
Mineralys' New Chief Medical Officer Receives 4-Year Equity Awards - Stock Titan
How Investors May Respond To Mineralys Therapeutics (MLYS) Wider Q2 Loss, Lorundrostat PDUFA Date And Royalty Buyback - webull.com
Mineralys Therapeutics CMO David Rodman sells $58,785 in stock - Investing.com
Mineralys Therapeutics CMO David Rodman sells $58,785 in stock By Investing.com - Investing.com Australia
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $58,785.30 in Stock - MarketBeat
Mineralys Therapeutics (MLYS) CMO exercises options, sells 2,170 shares under plan - Stock Titan
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down After Earnings Miss - MarketBeat
Mineralys Therapeutics, Inc. Stock 12‑Month Price Target Cut to $48.5, Implies 77% Upside - TradingView
Mineralys Therapeutics, Inc. Stock 12‑Month Price Target Cut to $48.75, Implies 78% Upside - TradingView
Transcript : Mineralys Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance UK
Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Mineralys Q2 Results: Net Loss Widens To $241.1 Million - scanx.trade
Mineralys Therapeutics Q2 Earnings Call Highlights - MarketBeat
MLYS: Q2 2026 featured robust launch preparations, strategic capital moves, and strong lorundrostat data - TradingView
Mineralys Therapeutics (NASDAQ:MLYS) Announces Earnings Results - MarketBeat
Earnings call transcript: Mineralys Q2 2026 loss widens, shares fall after hours - Investing.com
How Mineralys Therapeutics Inc. (MLYS) Affects Rotational Strategy Timing - Stock Traders Daily
Why is Mineralys Therapeutics stock sliding today? - Investing.com
Why is Mineralys Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Mineralys Therapeutics, Inc. Q2 2026: Net loss $(241.1)M, EPS $(2.85) — 10-Q Summary - TradingView
Mineralys Therapeutics (NASDAQ: MLYS) widens loss but builds $661M cash war chest - Stock Titan
Mineralys Therapeutics Q2 Loss Widens - marketscreener.com
MINERALYS THERAPEUTICS ($MLYS) Releases Q2 2026 Earnings - Quiver Quantitative
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q2 Loss $2.85, vs. FactSet Est of $0.55 Loss - marketscreener.com
Mineralys Therapeutics earnings up next as losses expected to widen By Investing.com - Investing.com UK
Mineralys Therapeutics Appoints James J. Ferguson III as New Chief Medical Officer and Reports Q2 2026 Financial Results - Kalkine Media
Mineralys Therapeutics falls 8% on second quarter EPS miss By Investing.com - Investing.com Australia
Mineralys Therapeutics falls 8% on second quarter EPS miss - Investing.com India
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Press Release: Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Mineralys Therapeutics earnings up next as losses expected to widen - Investing.com
Janus Henderson Group PLC Has $537,000 Stock Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics (MLYS) Holds Near $27.38 as Consolidation Persists Between $26.01 Support and $28.75 ResistanceFloat Adjusted Cap - dars.gov.et
Mineralys Therapeutics (MLYS) – David Rodman files Rule 144 for stock sale - Stock Titan
FMR LLC reports 5.1% Mineralys Therapeutics (MLYS) stake in amended ownership filing - Stock Titan
0.86%
0.31%
자본화:
|
볼륨(24시간):